Nobilis Therapeutics to Present at CapCon 2020 Venture Conference
October 30, 2020 09:00 ET | Nobilis Therapeutics, Inc.
PORTLAND, Ore., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Nobilis Therapeutics, a late stage biotechnology company that is developing a drug-device combination for treatment of psychiatric disorders will...
Nobilis Therapeutics’ NBTX-001 shows promise in treatment of patients with Panic Disorder
June 14, 2017 13:34 ET | Nobilis Therapeutics, Inc.
PORTLAND, Ore., June 14, 2017 (GLOBE NEWSWIRE) -- Nobilis Therapeutics, Inc. announced today that the results of the clinical trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in...
Nobilis Therapeutics Receives a Notice of Allowance for a Patent Covering Treatment of Psychiatric Disorders With Noble Gases
June 12, 2017 18:57 ET | Nobilis Therapeutics, Inc.
PORTLAND, Ore., June 12, 2017 (GLOBE NEWSWIRE) -- Nobilis Therapeutics announced today that the patent that it had exclusively licensed from Partners HealthCare/McLean Hospital (an affiliate of...